NetworkNewsBreaks

FridayMay 14, 2021 1:34 pm

NetworkNewsBreaks – Healthtech Solutions Inc.’s (HLTT) Latest Acquisition Brings in Innovative Team of Experts

Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, is among biotech players that have pivoted to a new model wherein multiple portfolio companies operate under one parent organization. Healthtech’s latest acquisition, Varian Biopharmaceuticals, brings to three the number of subsidiaries under its umbrella. “The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment,” reads a recent article. A precision oncology company, Varian specializes in developing atypical protein kinase…

Continue Reading

FridayMay 14, 2021 1:04 pm

NetworkNewsBreaks – Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) Leverages Radically Different Cultivation Approach

Pac Roots (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) has sought to differentiate itself by focusing on a genetics-based cultivation approach that enables production of premium-quality strains and products. This focus is influenced by the company’s resolution to avoid the fate that has befallen its competitors that have seen recent declines in market share. According to a recent article, PACR’s genetics-based cultivation approach has allowed it “to produce 50 super-elite strains and roughly 350 tested cultivars, which in turn has resulted in the company maximizing yields, boosting profitability and minimizing labor costs. In fact, as Pac Roots CEO explained, the company’s…

Continue Reading

FridayMay 14, 2021 12:40 pm

NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Potentially Uncover Innovative New Treatment Options

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. . . Cognilum delivers treatments…

Continue Reading

FridayMay 14, 2021 12:26 pm

NetworkNewsBreaks – Hunter Technology Corp. (TSX.V: HOC) (OTCQB: HOILF) (WKN: A2QEYH) (FSE: RWPM) Announces May 17 Webcast

Hunter Technology (TSX.V: HOC) (OTCQB: HOILF) (WKN: A2QEYH) (FSE: RWPM), a developer of digital marketplaces for global energy trading, has scheduled a webcast to connect with shareholders, investors and analysts. Hunter CEO Florian M Spiegl will host the webcast, which is scheduled for Monday, May 17, 2021, at 4:30 p.m. ET. Interested parties are encouraged to participate in the call and also submit questions before the call for Hunter Technology management to answer. Those questions can be sent via email at ir@huntertechnology.com or upon registering for the call. To register for the call, visit https://nnw.fm/OedYZ To view the full press…

Continue Reading

FridayMay 14, 2021 11:57 am

NetworkNewsBreaks – Knightscope Inc. Secures Additional $21.9M, Now Responsible for Two Largest Raises in StartEngine’s History

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), has successfully completed its most recent public offering, raising an additional $21.91 million. According to the update, Knightscope has now completed the two largest funding rounds in the history of the StartEngine platform. Knightscope has raised $90+ million from more than 28,000 investors and is poised to be an industry leader in the future of public safety and security. In addition, the company has reserved ticker symbol ‘KSCP’ with Nasdaq and is contemplating a possible public listing. “Knightscope’s long-term vision has an eye on the greater…

Continue Reading

FridayMay 14, 2021 11:10 am

NetworkNewsBreaks – WAX Blockchain Partners with Additional Well-Loved Entertainment Brands to Launch Digital Collectibles

Worldwide Asset eXchange(TM) (“WAX”), the “King of NFTs,” today announced partnerships with a number of the world’s most well-loved entertainment brands to release digital collectibles, called NFTs, on the WAX blockchain. The new partnerships include Robotech (Funimation and Harmony Gold), Five Nights at Freddy's (ScottGames), Bears vs Babies (Exploding Kittens), and The Princess Bride (Act III). The new partners join existing WAX partners that have already released hugely successful products on WAX, including Topps (Major League Baseball, Godzilla, Garbage Pail Kids), Capcom (Street Fighter), Atari, DeadMau5, Weezer, Reebok, William Shatner, Leonard Nimoy, and many more. Additionally, beginning in June of…

Continue Reading

FridayMay 14, 2021 11:09 am

NetworkNewsBreaks – Nextech AR Solutions Corp. (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29) Designated as a Preferred Vendor by Visit Tampa Bay

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, today announced a strategic partnership with Visit Tampa Bay. Designated as a preferred vendor by Visit Tampa Bay, the partnership affords the company the opportunity to connect with confirmed conferences for the city. Nextech is committed to building strategic partnerships with the world’s top destination marketing organizations and extending their reach through virtual and hybrid events. "We are thrilled to partner with Tampa Bay,” said Nextech CEO and Director Evan Gappelberg. “Nextech’s hybrid and virtual events platform keeps…

Continue Reading

FridayMay 14, 2021 10:58 am

NetworkNewsBreaks – Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Releases Q1 2021 Financial, General Meeting Report

Excellon Resources (TSX: EXN, EXN.WT) (NYSE American: EXN) (FSE: E4X2) has released its financial report for first quarter 2021, the period ended March 31, 2021. The report included both financial and operational highlights. Among the financial highlights for the company was the announcement that revenues had increased by 76% to $9.8 million during Q1 2020 compared to $5.6 million in Q1 2020, and gross profit reached $1.8 million, a $3 million improvement over first quarter 2020, which posted a $1.2 million loss. The company also reported total cash cost net of byproducts per silver ounce payable decreased by 13% to $13.43 compared to $15.35 the same quarter…

Continue Reading

FridayMay 14, 2021 10:58 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2021 Results, Provides Clinical Update and Business Outlook

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the quarter ended March 31, 2021. "2021 is poised to be an exciting year for the company. Throughout the first quarter, we have made continued development and regulatory progress on all fronts and are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM," said…

Continue Reading

FridayMay 14, 2021 10:57 am

NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is funded and targeting major milestones throughout this year. Corporate highlights for the company included the selection of five clinical sites around the United States for the upcoming phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of PCS499 in treating patients who…

Continue Reading